Back to TopExams and Tests
To determine whether
lung cancer may be causing your respiratory symptoms,
your health professional will evaluate your:
- Medical history, including your smoking history
and any symptoms you have now.
- Exposure to environmental and work
substances.
- Family history of cancer.
Initial exams and tests for suspected lung cancer include:
If your medical history, physical examination, or chest X-ray
suggest that lung cancer is present, your health professional may recommend
other tests, such as:
- CT scan of
the lungs, sometimes with transthoracic needle aspiration biopsy (TNAB) of a
lung nodule. A needle biopsy uses a needle inserted through the chest wall to
remove a sample of lung tissue (biopsy). This
usually is done if the abnormal lung tissue is located close to the chest wall.
Imaging procedures such as
ultrasound or
fluoroscopy may also be used to help guide the needle
to the right spot.
- Sputum cytology to evaluate the type of
any abnormal cells that are present in your mucus.
- Thoracentesis to take a sample of the fluid around
your lungs to evaluate the type of any abnormal cells. Thoracentesis is done if
you have a large collection of fluid around your lung (pleural
effusion). Thoracentesis is sometimes used to find out why you have
fluid collecting around your lung. Other times it is just to remove the fluid
and make it easier for you to breathe..
- Bronchoscopy
to take a biopsy of cells from your airway.
- Lung biopsy
to evaluate the type of any abnormal cells.
- Video-assisted
thoracoscopy (VATS) to take a biopsy of lung tissue through a small incision
between two ribs with the aid of a thin, lighted tube (videoscope) and small
surgical instruments.
After the type of lung cancer has been diagnosed, testing is done
to determine whether the cancer has spread (metastasized) to other organs in
your body and to determine the
stage of the cancer. Treatment of lung cancer is based
on the stage of the cancer. Tests used to determine whether the cancer has
spread may include:
- Mediastinoscopy to take biopsies of
lymph nodes to determine whether the cancer has spread
to the chest behind the breastbone (mediastinum).
- Endoscopic
ultrasound is sometimes done after a mediastinoscopy. In this test, a small
ultrasound probe at the end of the
endoscope is placed down the throat to the chest area.
The ultrasound can help detect cancer behind the breast bone or in lymph nodes
in the area. When endoscopic ultrasound and mediastinoscopy are both done, they
may be able to determine the stage of lung cancer better than mediastinoscopy
alone.8 Endoscopic ultrasound is not yet widely
available.
- CT scan of the brain, neck, abdomen, or
pelvis to determine whether the cancer has spread to these
areas.
- MRI of the brain to determine whether
the cancer has spread to the brain.
- Positron emission
tomography (PET). PET scanning can help determine whether a lung mass
(tumor) or enlarged lymph node is cancerous. PET may help determine whether
surgery is a treatment option. PET scanning may also be used after treatment to
see how well the treatment worked. PET scanning can be used to look for areas
of the liver, adrenal gland, or bone that may show where lung cancer has
spread.
- Bone scan to
determine whether the cancer has spread to the bones.
An
MRI of the spine may be done if there is concern that
the lung cancer has already spread to the spine. An
MRI of the chest may also be done, but a chest CT scan
is used most often to determine whether the cancer has spread in the
chest.
Lung function studies, including a
lung scan (ventilation and perfusion scans, V/Q scan),
may be done if surgery to remove cancer in all or part of a lung is being
considered. A person who has very poor lung function may not be a good
candidate for surgery.
If small cell lung cancer is diagnosed, additional testing may
include a
bone marrow aspiration and biopsy.
Early Detection
Several studies have examined the usefulness of chest X-rays,
sputum cytologies, or
spiral CT to screen for lung cancer in people who do
not have symptoms. Although these tests can sometimes diagnose early lung
cancer, they have not been proven to affect the long-term outcome (prognosis)
of lung cancer. Currently no medical professional organizations recommend
routine screening for lung cancer.9, 10 Experts continue to study the benefits of screening
tests.
Screening tests may aid in the early diagnosis of lung cancer,
but the tests can also show abnormal findings, such as nodules, that are not
cancer (false-positives). The finding of a
solitary pulmonary nodule (SPN) on a chest X-ray does
not always mean that cancer is present. Certain tests can help health
professionals determine whether an SPN is noncancerous (benign) or cancerous
(malignant). If cancer is suspected and the tissue is located close to the
chest wall, a needle biopsy is recommended to confirm or rule out the presence
of cancer. A needle biopsy uses a long needle inserted through the chest wall
to remove a sample of lung tissue. Imaging procedures such as
CT scan,
ultrasound, or
fluoroscopy usually are used to help guide the needle
to the right spot.
American Cancer Society (2005). What are the key
statistics for lung cancer? Detailed Guide: Lung Cancer.
Available online:
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_About_Lung_Cancer_15.asp?sitearea=.
Miller YE (2004). Lung cancer and other pulmonary
neoplasms. In L Goldman, D Ausiello, eds., Cecil Textbook of
Medicine, 22nd ed., pp. 1201–1208. Philadelphia: Saunders.
Crawford J (2004). Lung cancer. In DC Dale, DD
Federman, eds., ACP Medicine, section 12, chap. 8. New
York: WebMD.
Godtfredsen NS, et al. (2005). Effect of smoking
reduction on lung cancer risk. JAMA, 294(12):
1505–1510.
Jablons D, et al. (2003). Neoplasms of the lung. In LW
Way, GM Doherty, eds., Current Surgical Diagnosis and
Treatment, 11th ed., pp. 395–407. New York: McGraw-Hill.
Bain C, et al. (2004). Lung cancer rates in men and
women with comparable histories of smoking. Journal of the
National Cancer Institute, 96(11): 826–834.
National Toxicology Program, U.S. Department of Health
and Human Services (2005). Report on Carcinogens, 11th
ed. Available online: http://ntp-server.niehs.nih.gov/ntp/roc/toc11.html.
Annema JT, et al. (2005). Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer. JAMA, 294(8): 931–936.
Humphrey LL, et al. (2004). Lung cancer screening
with sputum cytologic examination, chest radiography, and computed tomography:
An update for the U.S. Preventive Services Task Force. Annals
of Internal Medicine, 140(9): 740–753.
National Cancer Institute (2005). Lung
Cancer PDQ: Screening–Health Professional Version. Available online:
http://www.cancer.gov/cancertopics/pdq/screening/lung/healthprofessional.
Winton T, et al. (2005). Vinorelbine plus cisplatin
vs. observation in resected non–small cell lung cancer. New
England Journal of Medicine, 352(25): 2589–2597.
Fox JL, et al. (2004). The effect of smoking status on survival following radiation therapy for non–small cell lung cancer. Lung Cancer, 44(3): 287–293.
Dasgupta P, et al. (2006). Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proceedings of the National Academy of Sciences, 103(16): 6332–6337.
Simon CJ, Dupuy DE (2005). Current role of
image-guided ablative therapies in lung cancer. Expert Review
of Anticancer Therapy, 5(4): 657–666.
International Adjuvant Lung Cancer Trial
Collaborative Group (2004). Cisplatin-based adjuvant chemotherapy in patients
with completely resected non–small-cell lung cancer. New
England Journal of Medicine, 350(4): 351–360.
Spira A, Ettinger DS (2004). Multidisciplinary
management of lung cancer. New England Journal of
Medicine, 350(4): 379–392.
Schabath MB, et al. (2005). Dietary phytoestrogens and
lung cancer. JAMA, 294(12): 1493–1504.
Goodman GE, et al. (2004). The beta-carotene and
retinol efficacy trial: Incidence of lung cancer and cardiovascular disease
mortality during 6-year follow-up after stopping beta-carotene and retinol
supplements. Journal of the National Cancer Institute,
96(23): 1743–1750.
Food and Drug Administration (2004). FDA statement on
Iressa. FDA Public Health Web Notification. Available
online: http://www.fda.gov/bbs/topics/news/2004/new01145.html.
U.S. Food and Drug Administration (2006). FDA approves new combination therapy for lung cancer. FDA News. Available online: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01488.html.
Chesnutt MS, Prendergast TJ (2005). Pulmonary
neoplasms. In LM Tierney Jr et al., eds., Current Medical
Diagnosis and Treatment, 44th ed., pp. 262–271. New York:
McGraw-Hill.
National Cancer Institute (2006). Small Cell Lung Cancer PDQ: Treatment—Health Professional
Version. Available online:
http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional.
Auperin A, et al. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New England Journal of Medicine, 341(7): 476–484.